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BACKGROUND. Desmoplastic and neurotropic melanoma (DNMM) occasionally
metastasizes to regional lymph nodes and extranodal sites. The value of sentinel
lymph node biopsy (SLNB) has not been demonstrated clearly for patients with
DNMM. The authors report on the utility of SLNB in the management of patients
with DNMM.
METHODS. The authors identified 33 patients with DNMM who were seen during a
5-year period in their institution who underwent lymphatic mapping and SLNB.
Clinical and histopathologic data were reviewed.
RESULTS. Thirty-three patients with DNMM underwent SLNB (mean Breslow
depth, 4.0 mm; median, 2.8 mm). There were 25 male patients and 8 female
patients with a median age of 61 years (range, 31– 86 years). Fifty-two percent of
tumors presented in the head and neck region, and 24% were associated with
lentigo maligna. Four of 33 patients (12%) without clinical evidence of metastatic
disease who underwent SLNB had at least 1 positive sentinel lymph node. No
additional positive lymph nodes were found in subsequent therapeutic regional
lymphadenectomy in any of these four patients.
CONCLUSIONS. SLNB detected subclinical metastases of DNMM to regional lymph
nodes. SLNB at the time of resection can provide useful information to guide early
treatment and, coupled with lymphadenectomy in positive patients, may limit
tumor spread and prevent recurrence at the draining lymph node basin. Cancer
2004;100:598 – 604. © 2003 American Cancer Society.
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In 1971, Conley et al. described an uncommon and distinct variant ofmelanoma that often presented as a hard, subcutaneous tumor of
fibrous appearance deep to a primary, superficial, melanotic lesion.1
These bulky tumors generally were located in the head and neck
region, often beneath lentigo maligna. The tumors were highly ma-
lignant, stubbornly recurring, and often metastasizing neoplasms. In
their seminal study, those authors observed regional lymph node
metastases in 3 of 7 patients (42%), pulmonary metastases in 4 of 7
patients (57%), and death related to disseminated disease in 4 of 7
patients (57%). The authors proposed the term desmoplastic malig-
nant melanoma for this unusual variant of spindle cell melanoma
accompanied by dense fibrosis. Eight years later, Reed and Leonard
observed that spindle cell melanomas with a dominant neuroid ap-
pearance and neurotropism often also manifested desmoplasia, and
those authors suggested that neurotropic melanoma is best consid-
ered a variant of desmoplastic melanoma.2 In their study of desmo-
plastic and neurotropic malignant melanoma (DNMM), Reed and
Leonard noted regional lymph node metastases in 2 of 16 patients
(12.5%), pulmonary metastases in 1 of 16 patients (6%), and death
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related to disease in 9 of 16 patients (56%). Other
investigators have observed similar behavior and met-
astatic rates for DNMM.3–10
In patients with DNMM without clinical evidence
of regional lymph node involvement, there is general
consensus that combined lymphatic mapping and
sentinel lymph node biopsy (SLNB) is the most appro-
priate strategy for obtaining staging informa-
tion.3,4,11–13 SLNB detects early metastases to regional
lymph nodes in a variety of malignancies.14 –23 Given
the low rate of associated morbidity and complica-
tions,24 SLNB seems an ideal staging tool for these
tumors. However, to our knowledge to date, the re-
sults reported in the literature have suggested that the
use of SLNB may not be reliable for DNMM. Indeed, in
4 recent studies involving a total of 62 patients with
DNMM who underwent SLNB, only 1 patient was di-
agnosed with a positive sentinel lymph node
(SLN).4,11–13 Given the infrequent involvement of SLNs
by DNMM, could SLNB lack sensitivity in detecting
lymph node metastasis for this tumor type? Or is SLNB
a sensitive technique with a low yield because DNMM
does not spread preferentially to lymph nodes? Should
a staging SLNB be performed at all for patients with
DNMM? To address these important questions, we
reviewed our experience with DNMM and the results
of SLNB for this tumor type.
MATERIALS AND METHODS
We searched the clinical data base of the University of
Michigan Multidisciplinary Melanoma Clinic for all
patients with DNMM who underwent SLNB from Oc-
tober, 1997 to October, 2002. Clinical data and his-
topathologic material were reviewed on all patients. At
our institution, indications for SLNB are clinically lo-
calized melanoma  1.0 mm Breslow depth or clini-
cally localized melanoma  1.0 mm with other poten-
tially adverse features, such as ulceration and
extensive vertical regression to at least 1.0 mm in
depth. Young patients with tumors exhibiting a high
mitotic rate ( 1 per mm) also are counseled regard-
ing SLNB. Contraindications for SLNB include poor
health/high surgical risk and the presence of sus-
pected palpable lymph node and/or distant metastatic
disease.
The procedures for lymphatic mapping and SLNB
used in our institution are similar to those described
previously.14 –16,23 Briefly, 1 mCi of unfiltered Tc99m-
sulfur colloid is injected intradermally at 4 points
around the primary tumor site 2– 4 hours prior to
surgery. Dynamic imaging is performed on the neck,
axillary, and groin regions to localize the SLN(s). The
patient is then brought to the operating room, where
1–2 cc of Lymphazurin blue dye (isosulfan blue) are
injected intradermally around the primary tumor site.
After induction of general anesthesia, the surgical sites
are prepared, sterilized, and draped. In vivo tracer
counts of the primary tumor site and lymph node
basins are measured with a hand-held  probe. An
incision is made in the lymph node basin(s) showing
increased radioactivity, within the confines of a puta-
tive radical lymphadenectomy incision. All blue-
stained, hot lymph nodes (defined as in vivo tracer
counts  100 cpm above background or 10% of the
cpm of the hottest detected lymph node, whichever
was less) are identified and removed. After harvesting
SLNs, the primary tumor site is excised with 1–2-cm
margins. All tissues are submitted in 10% buffered
formalin for histopathologic evaluation.
Primary tumor specimens were processed rou-
tinely in the histology laboratory. SLNs were sectioned
serially into 2–3-mm-thick sections and embedded in
paraffin. Two serial, 5-m sections of each SLN tissue
block were stained with hematoxylin and eosin (H&E)
for routine histologic examination. To confirm meta-
static disease identified on H&E-stained sections or
detect occult metastases, a 5-m section of each SLN
block was immunostained for S-100 protein (1:500
dilution; Dako Corporation, Carpinteria, CA) and for
melan-A (1:12.5 dilution; Dako Corporation).
Patients with at least one positive sentinel lymph
node were offered regional lymphadenectomy. All
lymph nodes retrieved from the lymphadenectomy
specimen were sectioned serially into 2–3-mm-thick
sections and were processed routinely in the histology
laboratory. H&E sections of the lymph nodes were
evaluated for metastatic tumor. Immunohistochemi-
cal stains (S-100 protein and melan-A) were not ob-
tained routinely on lymph nodes from the complete
lymph node dissection.
Clinicopathologic data from each patient were tab-
ulated (Table 1). For statistical comparisons of continu-
ous variables (Breslow depth with or without SLN me-
tastasis or mitotic rate with or without SLN metastasis),
we used a Student two-sample t test, assuming unequal
variance, with all P values two-tailed. Data were ana-
lyzed with Microsoft Excel Software (Microsoft Corp.,
Bellevue, WA). To test for a nonrandom association be-
tween categoric variables (site on head and neck or ul-
ceration or neurotropism) and SLN metastasis, we used
a 2-sided Fisher exact test because of the small number
in 50–75% of statistical cells. Data were analyzed with
MedCalc Statistic Software (MedCalc, Mariakerke, Bel-
gium). This study was conducted under an exemption
granted by the University of Michigan Institutional Re-
view Board for Human Subject Research.
RESULTS
We identified 33 patients (4%) with DNMM from our
data base of 836 patients with melanoma who under-
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went wide local excision and SLNB between October,
1997 and October, 2002 (Table 1). There were 25 male
patients and 8 female patients with a median age of 61
years (range, 31– 86 years). Tumors measured 4.0 mm
in mean Breslow thickness (median, 2.8 mm; range,
0.8 –9.0 mm). Tumors were located in the head and
neck region (n  17 patients), back and trunk (n  7
patients), and limbs (n  9 patients). A preexisting in
situ melanoma was identified in 15 of 33 patients
(45%), including lentigo maligna (n  8 patients), su-
perficial spreading (n  6 patients), and acral lentigi-
nous (n  1 patient) types. Nearly all were deeply
invasive into reticular dermis and subcutis (Clark level
IV and V). In the primary tumors, neurotropism was
observed in 14 tumors, 3 of which metastasized to
SLNs. Six tumors were ulcerated, two of which metas-
tasized to SLNs. None of the primary tumors demon-
strated angiolymphatic spread or satellitosis in histo-
logic sections. The dermal mitotic rate ranged from
 1 mm2 to 10/mm2.
Of 33 patients with DNMM who underwent SLNB,
30 patients underwent tumor resection and SLNB at
our institution. Four of 33 patients (12%) had 1 or
more positive SLNs. In one patient with DNMM aris-
ing in the scalp (Fig. 1), tumor metastasized to two of
six SLNs in the left neck (Fig. 2). In another patient
with DNMM from the neck (Fig. 3), tumor spread to an
SLN in the neck (Fig. 4). In both patients, metastatic
tumor retained a spindled appearance and elicited a
fibrosing reaction that obliterated the subcapsular si-
TABLE 1























1 Male 70 Scalp LM 6.0 V 3 Present Present Left neck 2/6 0/27 LNs in LAD
AWOD (4)
2 Male 66 Left neck LM 3.7 IV 2 Present None identified Left neck 1/1 0/19 LNs in LAD
AWOD (6)
3 Female 47 Midback None identified 4.8 IV 1 None identified Present Left axilla 1/3 0/31 LNs in LAD
AWOD (8)
4 Male 31 Right foot AL 2.8 V 1 None identified Present Right groin 2/2 0/20 LNs in LAD
AWOD (17)
5 Male 68 Left shoulder None identified 2.6 IV  1 None identified None identified Back  neck 0/3 AWOD (66)
6 Female 37 Left chin None identified 5.3 IV 1 None identified Present Left neck 0/1 AWOD (37)
7 Male 53 Right arm None identified 0.8 IV  1 None identified None identified Right axilla 0/1 AWOD (22)
8 Male 65 Left neck LM 2.4 IV  1 None identified None identified Left parotid 0/1 LTFU
9 Male 69 Scalp LM 1.8 IV 6 None identified None identified Left neck 0/2 AWOD (4)
10 Female 68 Back SSM 2.5 IV 1 None identified None identified Right axilla 0/2 AWOD (17)
11 Male 60 Left shoulder SSM 7.8 IV  1 None identified None identified Left axilla 0/2 AWOD (12)
12 Male 81 Right arm None identified 9.0 V 1 Present Present Right axilla 0/1 AWOD (25)
13 Male 80 Left lower lip None identified 5.0 IV  1 None identified Present Left submental 0/4 LTFU
14 Female 50 Left arm None identified 1.9 IV  1 None identified None identified Left axilla 0/4 AWOD (4)
15 Female 55 Left arm None identified 1.5 IV  1 Present None identified Left axilla 0/2 Developed lung
nodules; LTFU
16 Male 86 Left cheek None identified 4.7 V 1 None identified Present Left neck 0/2 AWOD (7)
17 Male 56 Right temple None identified 9.0 V  1 None identified Present Right neck 0/2 Mets to lung and to
1 right neck LN:
DOD (20)
18 Female 42 Posterior neck None identified 6.0 V  1 Present Present Bilateral neck 0/6 AWOD (53)
19 Male 74 Left ear None identified 1.9 IV  1 None identified None identified Left cervical 0/2 AWOD (37)
20 Male 37 Scalp None identified 8.2 V  1 None identified Present Right neck 0/2 AWOD (5)
21 Male 78 Right leg SSM 1.1 V 1 None identified None identified Right groin 0/2 AWOD (3)
22 Male 58 Midback None identified 3.4 IV 1 None identified None identified Right axilla 0/4 AWOD (14)
23 Male 49 Right arm SSM 1.9 IV  1 None identified None identified Right axilla 0/1 AWOD (38)
24 Male 59 Left cheek LM 1.9 IV  1 None identified Present Left cervical 0/1 AWOD (39)
25 Male 78 Scalp None identified 8.5 V 1 None identified None identified Left neck 0/1 AWOD (2)
26 Male 73 Left shoulder None identified 1.0 IV 1 None identified None identified Left supraclav 0/1 AWOD (9)
27 Male 79 Scalp LM 2.6 V 1 None identified Present Left neck 0/3 AWOD (10)
28 Male 40 Scalp LM 5.5 V  1 None identified Present Left neck 0/4 AWOD (39)
29 Male 64 Chest wall SSM 7.8 IV  1 None identified None identified Bilateral axilla 0/5 AWOD (24)
30 Male 47 Right back SSM 7.0 IV 4 Present Present Bilateral groin 0/2 AWOD (7)
31 Male 60 Scalp None identified 1.7 IV 10 None identified None identified Bilateral neck 0/2 AWOD (13)
32 Female 63 Right arm None identified 1.6 IV  1 None identified None identified Right axilla 0/1 AWOD (45)
33 Female 61 Right neck LM 0.9 IV  1 None identified None identified Right cervical 0/1 AWOD (2)
SLN: sentinel lymph node; LM: lentigo maligna type; LNs: lymph nodes; LAD: lymphadenectomy; AWOD: alive and well without disease; AL: acral lentiginous type; LTFU: lost to follow-up; SSM: superficial spreading
type; Mets: metastases; DOD: died of disease; supraclav: supraclavicular.
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nus and expanded the lymph node capsule (Figs. 2, 4).
In two patients with DNMM from the midback region
(Fig. 5) and right foot (Fig. 6), tumor metastasized to
one of three left axillary SLNs and to two of two right
groin SLNs, respectively. In both patients, a few clus-
ters of tumor cells displayed an epithelioid morphol-
ogy (Figs. 7, 8). No additional involved lymph nodes
were identified in subsequent regional lymphadenec-
tomy.
No statistically significant association was noted
between several clinicopathologic factors and SLN
metastasis. The mean Breslow depth of tumors that
metastasized to SLNs was not significantly different
from the mean Breslow depth of tumors that did not
metastasize to SLNs (4.33 mm vs. 3.98 mm; P  0.70).
The mean mitotic rate of tumors that metastasized to
SLNs (1.75/mm2) was not significantly different from
the mean mitotic rate of tumors that did not metas-
tasize to SLNs (1.00/mm2; P  0.27). There was no
FIGURE 2. A sentinel lymph node from Patient 1 demonstrated obliteration
of the subcapsular sinus and thickening of the lymph node capsule. Highly
atypical, S-100 positive spindle cells of desmoplastic and neurotropic mela-
noma (arrowheads and insets) infiltrated the lymph node capsule and elicited
a fibrosing reaction.
FIGURE 3. From Patient 2, desmoplastic and neurotropic melanoma (DNMM)
(leftward arrowheads) arose on sun-damaged skin beneath in situ melanoma,
lentigo maligna type (upward arrowheads). Often observed in DNMM, nodular
lymphoid aggregates (asterisk) were present within and peripheral to the
tumor. Again, tumor cells characteristically elicited a fibrosing reaction in the
dermis (inset).
FIGURE 4. A sentinel lymph node from Patient 2 showed a pattern of tumor
spread to the lymph node similar to that in Patient 1. There was obliteration of
the subcapsular sinus accompanied by infiltration of the lymph node capsule
(asterisk) by highly atypical, S-100 positive spindle cells of desmoplastic and
neurotropic melanoma (arrowheads and insets).
FIGURE 1. Atypical spindle cells of desmoplastic and neurotropic melanoma
from Patient 1 invading the superficial and deep dermis. Tumor cells in the
sclerotic dermis (arrowhead in inset A) surrounded and grew around nerve
bundles (asterisk in inset A). In immunostained sections, nerve bundles (as-
terisk in inset B) and surrounding melanoma cells (arrowhead in inset B) were
found to express S-100 protein.
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significant association between SLN metastasis and
site on the head and neck (P  1.00), tumor ulceration
(P  0.14), or neurotropism (P  0.29).
Clinical follow-up was available on 30 of 33 pa-
tients (91%) who underwent SLNB, ranging in dura-
tion from 2 months to 66 months (median, 13.5
months; mean, 20 months). All four patients with pos-
itive lymph node status were alive and well without
clinically apparent disease at the time of this report. Of
the remaining 29 patients with negative SLNs, the
tumor recurred in a regional lymph node and metas-
tasized to the lungs of one patient (Patient 17) 9
months and 13 months after SLNB, respectively. The
patient died of disseminated disease 20 months after
the initial diagnosis of DNMM. One patient (Patient
15) developed lung nodules that were suspicious for
metastatic disease but was lost to follow-up. Two pa-
tients with negative SLNs were lost to follow-up. The
remaining 25 patients with negative SLNs were alive
and well without evidence of disease at the time of last
follow-up.
DISCUSSION
An analysis of the experience with DNMM at the Uni-
versity of Michigan Cancer Center confirms many of
the observations in the literature regarding the pre-
FIGURE 6. Desmoplastic and neurotropic melanoma arising in acral lentigi-
nous melanoma from the foot of Patient 4 showed highly atypical spindle
melanocytes infiltrating the dermis (arrowheads in inset A). Tumor cells
displayed neurotropism surrounding and invading nerve twigs in deep dermis
(arrowheads in inset B).
FIGURE 8. In the sentinel lymph node from Patient 4, a few clusters of
melan-A positive, atypical epithelioid cells were identified in the parenchyma
and peritrabecular areas, consistent with metastatic melanoma.
FIGURE 5. Desmoplastic and neurotropic melanoma from Patient 3 showed
a small population of conventional epithelioid melanoma cells (asterisk and
inset A) in the upper part of the tumor and atypical spindle cells invading the
deep dermis accompanied by prominent desmoplasia (inset B).
FIGURE 7. One of a few clusters of metastatic epithelioid melanoma in the
lymph node parenchyma from Patient 3 was found to express melan-A.
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sentation and natural history of this uncommon mel-
anoma. DNMM typically presents in the head and
neck region of elderly males.3 The tumor most often
occurs in lentigo maligna (42%) and, in the majority of
patients, is deeply invasive at the time of diagnosis.3 In
our study, DNMM presented predominantly in the
head and neck region (52%) of males (76%) with a
mean age of 61 years. Tumors were deeply invasive
(mean Breslow depth, 4.0 mm; median Breslow depth,
2.8 mm), and many were associated with lentigo ma-
ligna (24%).
Findings from this study also offer new insights
into the clinical significance of SLNB for this tumor.
Specifically, we document the utility of SLNB in de-
tecting early metastases of DNMM to regional lymph
nodes. The incidence of lymph node metastasis has
been estimated to range from 8% to 15% for DNMM,11
although a few studies have observed higher rates
(Table 2). Of 33 patients with DNMM who underwent
SLNB, positive SLNs were identified in 4 of 33 patients
(12%), which is consistent with the incidence of lymph
node metastasis reported in the literature.3–11
Cumulative data in the literature suggest that,
compared with non-DNMM melanomas of the same
depth, DNMM metastasizes less commonly to re-
gional lymph nodes.3,11–13 The reported incidence of
lymph node metastasis in non-DNMM melanomas
with a Breslow thickness of 1.5– 4.0 mm ranges from
19% to 28.7%.25,26 In our institutional data base, 22%
of non-DNMM melanomas with a mean Breslow
thickness of 2.9 mm had positive SLNB results. In
contrast, only 12% of DNMM with an mean Breslow
thickness of 4.0 mm had positive SLNB results, sup-
porting the observation that, although DNMM is often
deeply invasive, the tumor metastasizes to lymph
nodes less frequently than conventional melanoma.
Despite the lower incidence of lymph node in-
volvement in DNMM compared with non-DNMM
melanoma, an argument can be made for performing
SLNB in DNMM. It has been proposed that SLNB
should be considered when a primary melanoma
measures thicker than 1 mm and should be applied
selectively for tumors that measure  1.0 mm, if ul-
ceration is present, and perhaps if the lesion is inva-
sive to Clark level IV or higher.27 If SLNB should be
considered for melanomas 1 mm thick, with an ex-
pected SLN positivity of about 8%,26 then the higher
observed SLN positivity rate of 12% for DNMM offers
a reason to perform the procedure.
It is important for the histopathologist to recog-
nize several possible pitfalls in the interpretation of
SLNs for DNMM. First, the microscopic features of
metastatic DNMM can vary and may not resemble the
primary tumor.1,2 In lymph nodes, their histology can
manifest as that of classic malignant melanoma, that
of a desmoplastic spindle cell tumor, or both.1,2 In two
patients in the current study, melanoma cells in SLNs
displayed an epithelioid morphology, even though the
primary tumor consisted predominantly of spindle
cells (Figs. 5– 8). In two other patients, metastatic
DNMM exhibited a spindle cell morphology with as-
sociated desmoplastic stroma resembling the primary
tumor (Figs. 1– 4). Second, interpretation may be com-
plicated by the presence of only a few tumor cells in
the SLNs. In two patients in the current study, only a
few clusters of melanoma cells were identified in SLN
sections (Figs. 7, 8). Immunohistochemical stains for
melan-A were pivotal in identifying microscopic me-
tastases in both patients. Third, although DNMM usu-
ally expresses S-100 protein, the tumor often does not
mark for more specific melanocyte markers, such as
HMB-45, and inconsistently expresses melan-A.28,29
TABLE 2

















Devaraj et al.6 67 5.78 4/13 (31.0) 4/13 (31.0) 3/13 (23.0) Mean, 40.0
Quinn et al.3 61 2.5 26/280 (9.0) NR 27.8% 60.0
Smithers et al.7,8 61 4.5 6/45 (13.0) 2/45 (4.0) 5/45 (11.0) 1–108
Beenken et al.9 63 5.75 2/13 (15.4) 5/13 (38.0) 4/13 (30.0) Mean, 55.0
Payne et al.4 63 2.6 3/30 (10.0) 2/30 (6.0) 1/30 (3.0) Mean, 18.0
Reed and Leonard2 59 NR 2/16 (12.5) 1/16 (6.0) 9/16 (56.0) 24–108
Egbert et al.10 61 NR 3/25 (12.0) NR 3/25 (12.0) Mean, 32.4
Carlson et al.5 59 4.1 4/28 (14.0) 3/28 (11.0) 3/26 (11.5) Mean, 36.0
Conley et al.1 53 NR 3/7 (42.0) 4/7 (57.0) 4/7 (57.0) NR
NR: not reported.
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We encountered two such patients who were negative
for melan-A (Figs. 1– 4). However, a positive diagnosis
was made on each case based on the combined
histopathologic and immunophenotypical features
(highly atypical, S-100 positive spindle cells obliterat-
ing the lymph node sinuses and abnormally expand-
ing the capsule).
The use of SLNB for DNMM has been reported in
4 studies involving a total of 62 patients with only 1
SLNB (1.6%) that produced positive results.4,11–13 In
contrast, in the current study, we present a group of 33
patients in which SLNB detected occult lymph node
disease in 4 patients (12%). SLNB allowed early detec-
tion of occult, metastatic DNMM, which, coupled with
lymphadenectomy, may have limited tumor spread
and prevented tumor recurrence at the draining
lymph node basin in these four patients. Whether
early detection and treatment of lymph node metas-
tasis improves overall survival is not clear at this time,
and long-term follow-up of these patients will be re-
quired to make this determination.
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